$100+ Billion spent on myriad of acquisitions across Pharma and Biotech industries in H1 2018
Lloyd Price
JULY 5, 2018
In March, GlaxoSmithKline dropped $13 billion to acquire full control of a consumer health unit. As BioSpace noted when the deal was announced, Takeda will also take on a significant amount of debt through the deal, sending the price tag closer to $80 billion when that amount is included. The deal will help open U.S.
40 
Let's personalize your content